5 Conclusion
In our study, a UPLC-MS/MS method for analysis of imatinib was
established. Under the optimized experimental conditions, this method
showed good selectivity and reliability and has been used for routine
imatinib monitoring for patients receiving adjuvant and neoadjuvant
therapy for GIST. We found that gender may be the affecting factor of
imatinib Cssmin. Whether the imatinib
Cssmin threshold of 1100 ng/mL could be contributed to
oncotherapy for patients with adjuvant and neoadjuvant therapy for GIST
should be further studied.